Abstract:Abstract Background and Aims Multiple myeloma(MM) is the 2nd most common haematological neoplasm and a largely heterogeneous malignancy in what regards cytogenetics, clinical presentation, therapy response and overall survival. Renal impairment related to MM is known to be diagnosed in at least 50% of patients during the course of this disease. Recent studies have shown an association between high-risk cytogenetic abnormalities(CA) with lower disease-free survival and lower overall survival. However, there is still scarce knowledge in what regards the kidney implications of MM CA. The purpose of this study is to identify an association between MM cytogenetic profile and acute kidney injury(AKI) at presentation. Method This was a single-centre retrospective cohort study of all adult patients diagnosed with MM between Jan./2018-Dec./2021 in a tertiary care university hospital in Lisbon. Diagnosis of MM was made according to the International Myeloma Working Group criteria. Patient variables were collected from individual clinical records. Categorical variables were described as the total number and % and continuous variables as median(P25-P75). Normally distributed continuous variables were compared with the Student-t-test, non-normally distributed continuous variables with the Mann-Whitney U-test and categorical variables with the chi-squared test. A multivariable backward stepwise regression model was performed to investigate predictors for AKI. Statistical significance was defined as p<0.05. Analyses were performed with the statistical software package STATA 16.0. Results 114 patients were included[median age 69.8±11.4 years, 48.1% male, 90.4% caucasian]. 61.5% had hypertension, 21.2% diabetes and 33.9% CKD with baseline GFR of 75.2(49.5-92.3)mL/min/1.73m2. 25% were on RAAS inhibitors, 5.8% on NSAID and 9.6% on bisphosphonate. The most common heavy chain was IgG(58.8%), the most common light chain was Kappa(52.4%) and 12.8% were isolated light chain-MM. 56.5% had a Revised International Staging System(R-ISS) of 2. Median serum M component was 4.5(2.8-7.9)g/dL, dFLC 247.8(48.9-1059.2) mg/L and plasma cells in bone marrow(BM) aspirate 39.0(15.5-67.0)%. 15.4% had hypercalcaemia, 68.9% Bence Jones protein, 3.8% secondary amyloidosis and 18.3% extramedulary disease. 38 patients had CA: 36.5% primary, 35.6% secondary and 33.7% high risk CA. Most patients were treated with proteasome inhibitors(75.0%), 26.9% were submitted to BM transplant and 59.2% had a complete or very good partial response to treatment. 13(12.5%) relapsed and 26(25.0%) died. AKI was present in 31.1% of patients and 11.7% needed renal replacement therapy.On univariable analysis, variables with impact on AKI were diabetes (34.3% vs 15.5%, p = 0.03), CKD (62.5% vs 21.1%, p<0.001), hypercalcemia (28.1% vs 9.9%, p = 0.018), higher R-ISS (p<0.001), beta 2-mycroglobulin (p<0.001), % of plasma cells in BM aspirate (p = 0.002) and dFLC (p = 0.01), lower baseline GFR (p<0.001) and the presence of CA (53.1% vs 28.2%, p = 0.015), primary CA (53.1% vs 28.2%, p = 0.015) and high-risk CA (46.9% vs 28.2%, p = 0.064). On multivariable analysis, the presence of CA[OR 3.094 (1.018-9.403), p = 0.046] and previous CKD[OR 8.069(2.430-26.796), p = 0.001] showed an independent association with AKI at presentation. Conclusion Our study suggests there is an association between CA and AKI at presentation, which may implicate a worse overall survival, have treatment implications and highlights the need for prevention and early diagnosis.MM cytogenetics is being studied since the 2000s and research is still on going in the attempt of creating a MM profile that can guide prevention, treatment and predict outcomes. It is known that renal impairment in MM particularly at diagnosis is associated with lower overall survival. However, to the best of our knowledge, the potential association between cytogenetic profile and AKI has not been thoroughly studied.

Multiple Myeloma and Acute Kidney Injury: Mechanisms Involved

#3709 KIDNEY IMPAIRMENT AT DIAGNOSIS IN MULTIPLE MYELOMA: THE NEPHROLOGIST PERSPECTIVE

Update on kidney injury caused by multiple myeloma

The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease

The renal damage and mechanisms relevant to antitumoral drugs

Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study

Management of multiple myeloma patients with renal disease

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

Monoclonal gammopathy of renal significance from the perspective of nephrologists

Multiple myeloma, immunotherapy and minimal residual disease

Modeling the Effects of Multiple Myeloma on Kidney Function

Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States

#6719 ACUTE KIDNEY INJURY AND MULTIPLE MYELOMA-THE ROLE CYTOGENETICS: A COHORT STUDY

Myeloma Cast Nephropathy and COVID-19: A Case Report of Multiple Myeloma Presenting as Acute Kidney Injury in the Setting of COVID-19

Crystalline Light Chain Casts and Hypercalcemia Induced Acute Kidney Injury: A Rare Presentation of Multiple Myeloma

Kidney involvement in myelodysplastic syndromes

Acute Kidney Disease in Oncology: A New Concept to Enhance the Understanding of the Impact of Kidney Injury in Patients with Cancer

Macrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted Therapy

Multiple myeloma in the marrow: pathogenesis and treatments

Multiple myeloma complicated with light chain cast nephropathy with focal amyloidosis: A case report

Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center.